Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118905352 | 11890535 | 2 | F | 201512 | 20160721 | 20160105 | 20160727 | EXP | PHHY2015LB167320 | NOVARTIS | 0.00 | A | F | Y | 0.00000 | 20160727 | MD | LB | LB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118905352 | 11890535 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | Y | 22068 | 600 | MG | CAPSULE | QD | |||||
| 118905352 | 11890535 | 2 | SS | HYDREA | HYDROXYUREA | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118905352 | 11890535 | 1 | Chronic myeloid leukaemia |
| 118905352 | 11890535 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118905352 | 11890535 | OT |
| 118905352 | 11890535 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118905352 | 11890535 | Cardiac disorder | |
| 118905352 | 11890535 | Diarrhoea | |
| 118905352 | 11890535 | Epistaxis | |
| 118905352 | 11890535 | Fatigue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118905352 | 11890535 | 1 | 201511 | 201512 | 0 |